Top 10 ASX Dividend Stocks for Sep 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesBraveheart Bio, Inc. Common Stock

Braveheart Bio, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
20.62 USD -2.75 ( 11.77%)
Last update at 2026-09-25T20:15:00Z
VOLUME
469760
Market Cap
2404.94M

Momentum Score

…

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
20.53
Low
23.86
High
52 Week Price Range
24.31
Low
32.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Braveheart Bio, Inc. is a Nasdaq-listed biotechnology company; public disclosures about its pipeline and operations are limited. Its long-term growth may depend on clinical progress, regulatory approvals and strategic partnerships that could support commercialization. Investors may find the company attractive for potential upside tied to successful program milestones.
Material risks include clinical or regulatory setbacks, high cash burn with potential dilution from additional financing, limited liquidity and the operational challenges and competitive pressures common to early-stage biotechs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
23.37
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
-
ROCE
-5.36%
Diluted EPS TTM
-1.58

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31
Type yearly
Date 2025-12-31
Income before tax -66.05M
Net income -66.05M
Selling general administrative 3.02M
Operating income -4.50M
Interest income 0.70M
Net interest income 0.70M
Total revenue 0.00M
Total operating expenses 4.50M
Total other income expense net -62.24M
Net income from continuing ops -66.05M
Breakdown 2025-12-31
Type yearly
Date 2025-12-31
Total assets 89.35M
Other current assets 0.12M
Total liab 155.22M
Total stockholder equity -65.87M
Capital stock 0.00M
Retained earnings -66.05M
Cash 89.16M
Total current liabilities 5.24M
Total current assets 89.28M
Accounts payable 1.06M
Non currrent assets other 0.07M
Non current assets total 0.07M
Breakdown 2025-12-31
Type yearly
Date 2025-12-31
Total cash from financing activities 124.74M
Net income -66.05M
Change in cash 89.16M
Begin period cash flow 0.00M
End period cash flow 89.16M
Total cash from operating activities -2.01M
Issuance of capital stock 124.74M
Capital expenditures 33.57M
Change in working capital 1.62M
Stock based compensation 0.18M
Other non cash items 62.24M
Free cash flow -35.58M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
BRVE
Braveheart Bio, Inc. Common Stock		 -2.75
11.77%		 20.62 - - - -
NVO
Novo Nordisk A/S		 0.18
0.47%		 38.80 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 3.81
0.73%		 526.19 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 -7.98
1.00%		 788.04 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 1010.26 45.77 31.25 13.84 7.12

Profile*

Braveheart Bio, Inc. Common Stock

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

One Letterman Drive, San Francisco, CA, United States, 94129

415 707 6312

https://www.braveheart.bio

49

Name Title Year Born
Dr. Travis Murdoch B.S., M.D., M.Sc. CEO, President & Director 1985
Mr. James Paul Rickey CPA Chief Financial Officer 1979
Ms. Michele A. Anderson Chief Development Officer 1967
Mr. Marc Evanchik M.S. Chief Scientific Officer 1973
Ms. Natalie Dement J.D. VP & Head of Legal NA
Mr. Timothy Y. Zhou Director of Corporate Development NA
Ms. Steph Palencia Associate Director of Human Resources & Office Manager NA
Ms. Brittany de Temple Senior Vice President of Development Operations NA
Dr. Emil M. deGoma M.D. Chief Medical Officer 1976
Mr. Tyler Chavez Ph.D. Chief Business Officer 1989

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ATM
AUD 1.06
+8.67%
G6M
AUD 3.49
+7.06%
NST
AUD 23.47
+6.15%
INA
AUD 4.76
+5.78%
MEZ
AUD 4.53
+5.35%
KAR
AUD 1.55
-12.89%
NMG
AUD 0.07
-12.66%
MI6
AUD 0.84
-10.64%
BRE
AUD 3.56
-9.64%
CXO
AUD 0.32
-8.70%

Equity Sectors*

  • Basic Materials

    -2.53%

  • Communication Services

    -0.20%

  • Consumer Cyclical

    -0.30%

  • Consumer Defensive

    -0.14%

  • Energy

    -1.70%

  • Financial Services

    -0.11%

  • Healthcare

    -0.80%

  • Industrials

    -0.68%

  • Real Estate

    +0.72%

  • Technology

    -0.78%

  • Utilities

    +2.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…